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Abstract
Background: The goal of our study was to determine the impact 
of gastrointestinal bleeding (GIB) on in-hospital outcomes among 
acute respiratory distress syndrome (ARDS) patients, and subse-
quently determine the potential risk factors for the development of 
GIB.
Methods: ARDS patients with and without GIB were identified using 
the National Inpatient Sample (2002 - 2012). Linear regression analy-
sis was used to assess impact of GIB on in-hospital mortality, length 
of stay and total charges. Univariate logistic regression was used to 
determine associated odds ratios (OR) for causes of ARDS and com-
mon comorbid conditions.
Results: We identified 149,190 ARDS patients. The incidence of GIB 
was the highest among patients > 60 years (P < 0.001). GIB was as-
sociated with longer hospitalization days (7.3 days versus 11.9 days, 
P < 0.001), higher mortality (11% versus 27%, P < 0.001) and greater 
economic burden ($82,812 versus $45,951, P < 0.001). GIB was com-
mon in cirrhosis (OR: 8.3), peptic ulcer disease (OR: 3.7), coagulopa-
thy disorders (OR: 3.003), thrombocytopenia (OR: 2.6), anemia (OR: 
2.5) and atrial fibrillation (OR: 1.5). ARDS secondary to aspiration 
pneumonia (OR: 2.0), pancreatitis (OR: 2.0), sepsis (OR: 1.6) and 
community acquired pneumonia (OR: 0.8) was more likely to have 
GIB.
Conclusion: Our study demonstrates that GIB in ARDS patients is 
associated with significant increased mortality, hospitalization and 
health care cost.
Keywords: Gastrointestinal bleeding; ARDS; National Database 
Analysis
Introduction
Acute respiratory distress syndrome (ARDS) is a complex 
disorder characterized by diffuse capillary endothelial and al-
veolar damage. Early reports in 1978 described an increased 
incidence of gastrointestinal bleeding (GIB) at a rate of 11 out 
of 13 ARDS patients compared to 4 out of 44 mechanically 
ventilated chronic obstructive pulmonary disease (COPD) pa-
tients [1].
Overt GIB is a known complication ranging between 
1.5% and 8.5% in critically ill patients [2-4]. In this setting, 
prolonged mechanical ventilation for >48 h and coagulopathy 
are well-described risk factors for gastrointestinal bleeding 
[5]. ARDS appears to be an additional condition that sets the 
stage for developing a specific gut injury leading to bleeding. 
The underlying stress-related mucosal damage (SRMD) in 
this setting could range from asymptomatic superficial lesions 
and occult GIB to deeper mucosal injury and overt clinically 
significant hemorrhage [6]. The pathophysiology of SRMD is 
explained by disruption of the gastric mucosal barrier due to 
reduced gastric blood flow, increased reflux of bile salts and 
uremic toxins along with reperfusion injury [1, 7]. SRMD is 
responsible for the majority of GIB in mechanically ventilated 
patients. It has been postulated that 75-100% of critically ill 
patients will have endoscopically detected stress-related mu-
cosal erosions and subepithelial hemorrhages within 24 h of 
their admission to the critical care unit [8-10].
The current standards in the management of ARDS fol-
lows a lung-protective strategy using low tidal volumes (TVs) 
and increased positive end-expiratory pressures (PEEP) to 
prevent atelectasis and support oxygenation. This increased 
PEEP results in decreased venous return and cardiac output, 
which leads to splanchnic hypoperfusion and ischemic injury 
to the gastric mucosa. This condition is also associated with 
increased plasma-renin-angiotensin-aldosterone activity and 
elevated catecholamines, which results in vasoconstriction and 
further compromise to the gastric blood flow [11-14].
To our knowledge, this is the first large-scale national da-
tabase analysis that looked at the incidence and predictors of 
GIB among hospitalized patients with ARDS.
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We conducted a study utilizing the National Inpatient 
Sample (NIS) database with the primary aim to determine the 
incidence of gastrointestinal hemorrhage among patients ad-
mitted with ARDS. As a secondary aim, we intended to ana-
lyze the comorbidities contributing to increased risk of GIB 
in those patients, and to evaluate the length of hospital stay, 
attributed health cost burden and mortality rates among ARDS 
patients with GIB versus those who did not develop GIB.
Patients and Methods
Data source
A retrospective longitudinal analysis of all adult patients (> 
18 years) admitted in the USA from 2002 to 2012 with the 
diagnosis of ARDS was performed using the NIS database. 
The NIS database was developed by the Health Care Cost and 
Utilization Project (HCUP) and is the largest publicly avail-
able all-payer inpatient care database available in the USA. 
This database is known for its utility in studying trends and 
outcomes of various diseases and procedures [15-17], and it 
comprises stratified data collected from 20% of US commu-
nity hospitals, in the form of de-identified information on indi-
vidual hospitalizations that includes demographics, insurance 
status, comorbidities, admission status, discharge diagnoses, 
procedures, outcomes, length of stay (LOS) and cost of hos-
pitalization.
Study population
Using the International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9-CM) codes, we identified 
all hospitalizations among adults > 18 years of age, admitted 
with a primary or secondary diagnosis of ARDS, from 2002 
through 2012. Hospitalizations with missing age, gender, ad-
mission and discharge diagnoses or mortality were excluded. 
We also collected variable etiologies of ARDS to include com-
munity-acquired pneumonia, aspiration pneumonia, sepsis or 
septic shock, pancreatitis and burns.
Definition of variables
The NIS variables were utilized to identify patients’ age, gen-
der and race. Age was divided into five categories: younger 
than 20 years, 20 - 39 years, 40 - 59 years, 60 - 79 years 
and older than 80 years. Race was divided into white, black, 
Hispanic, Asian or Pacific Islander, and Native American. A 
modified Charlson comorbidity index (CCI) was used to de-
fine the severity of the associated comorbid conditions. The 
scores ranged from 0 to 33 with higher scores correspond-
ing to a greater burden of comorbid disease and vice versa. 
Hospital bed size and its location as urban or rural were also 
taken into account. Hospitals that upheld an Accreditation 
Council for Graduate Medical Education-accredited residen-
cy program, a membership of the Council of Teaching Hospi-
tals, and/or had a full-time equivalent interns and residents to 
provide a patient ratio of 0.25 were considered as “teaching 
hospitals”. The cost of each hospitalization was calculated 
by merging the data with cost to charge ratio from the HCUP 
database. This was standardized and adjusted for each year. 
The cost of each year was adjusted in reference to the 2016 
US dollar value by using the consumer price index to account 
for inflation.
Outcomes
Our objectives were as follows: 1) the primary objective was 
to analyze the incidence of GIB in patients hospitalized with 
ARDS in a cohort group of individuals admitted between 2002 
and 2012; 2) the secondary objective was to investigate the 
independent predictors of GIB in patients with ARDS. We 
analyzed the following well-established comorbidities associ-
ated with GIB: alcoholism, past or current peptic ulcer dis-
ease (PUD), underlying liver disease, atrial fibrillation (AF), 
congestive heart failure (CHF), valvular heart disease, renal 
failure, anemia, past history of GIB, coagulation disorders, 
and gastrointestinal malignancies including esophageal, gas-
tric, small intestinal, colorectal cancers [18]. Established risk 
factors for the development of ARDS like sepsis and septic 
shock, aspiration pneumonia and community-acquired pneu-
monia, burns and pancreatitis were also studied [19]. We also 
compared the LOS and cost per hospitalization of patients with 
ARDS and GIB versus those who did not have GIB. Mortality 
rates between the two groups were also assessed.
Statistical analysis
ARDS patients were captured by ICD-9 code 518.82 whether 
ARDS was a primary or a secondary diagnosis. GIB in those 
patients was also extracted using the corresponding clinical 
classification software codes. A Chi-square test or analysis 
of variance (ANOVA) was accordingly used to identify the 
demographical differences between ARDS patients with and 
without GIB. A two-sample t-test was used to assess for im-
pact of GIB on in-hospital mortality, LOS and total charges 
for ARDS patients with or without GIB. A univariate logistic 
regression analysis was used to calculate odds ratios (OR) for 
causes of ARDS, comorbid conditions and their associations 
with the incidence of GIB. A Multivariate analysis of signif-
icant co-morbidities was then performed to account for any 
confounders among the significant comorbidities.
Results
A total of 149,190 patients (older than 18 years) were iden-
tified between 2002 and 2012 with a discharge diagnosis of 
ARDS. A total of 3,988 of those patients with ARDS devel-
oped GIB. The mortality rate during hospitalization was sig-
nificantly higher in patients with ARDS complicated by GIB 
reaching to 27% when compared to 11% in patients without 
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GIB (P < 0.001).
Table 1 shows the baseline characteristics and demograph-
ics of patients with ARDS with and without GIB. The mean 
age of patients with ARDS who had GIB was 67 years, and 
more than 7% of these individuals were over 60 years of age. 
There was no significant gender difference among the patients 
who had GIB. Asians and Pacific Islanders exhibited a sig-
nificantly higher risk of GIB when compared to other races 
(3.69%; P < 0.001). Patients who had GIB were more likely 
to have Medicare as their medical coverage provider (3.49%; 
P < 0.001). Most ARDS patients with GIB had CCI index > 
2. Patients with ARDS who had GIB had significantly longer 
length of hospital stay of 11.93 days (SD: 0.24; P < 0.001) 
as compared to 7.37 days (SD: 0.03; P < 0.001) for patients 
who did not develop a GIB. The mean hospital cost was also 
inflated in patients with GIB as compared to patients without 
GIB ($82,812 versus $45,951; P < 0.001).
Table 2 shows the various comorbidities that were associ-
ated with an increased risk of GIB. Patients with pre-existing 
gastrointestinal conditions like cirrhosis and peptic ulcer dis-
Table 1.  Baseline Characteristics and Demographics of ARDS Patients With and Without GIB
Demographics
GIB during hospitalization
P valueNo Yes
No. % No. %
Total 145,202 97.33 3,988 2.67
Age group (years) 29,466 99.49 151 0.51 < 0.001
  < 20
  20 - 39 11,863 98.26 210 1.74
  40 - 59 28,252 97.08 850 2.92
  60 - 79 43,518 96.49 1,581 3.51
  ≥ 80 31,917 96.4 1,193 3.6
Age, mean (SD) 53.38 (0.09) 66.58 (0.36) < 0.001
Race 75,133 97.18 2,184 2.82 < 0.001
  White
  Black 18,245 97.65 440 2.35
  Hispanic 14,666 97.96 305 2.04
  Asian or Pacific Islander 2,633 96.31 101 3.69
  Native American 840 98.13 16 1.87
  Other 3,659 97.31 101 2.69
Gender 75,315 97.47 1,556 2.53 0.008
  Female
  Male 69,701 97.2 1,591 2.8
Insurance
  Medicare 70,326 96.51 2,544 3.49 < 0.001
  Medicaid 27,919 98.40 454 1.60
  Private insurance 35,970 98.11 693 1.89
  Self-pay 5,877 96.96 184 3.04
  No charge 640 98.01 13 1.99
  Other 4,068 97.86 89 2.14
Hospital type
  Rural 21,264 97.85 468 2.15 < 0.001
  Urban non-teaching 50,658 97.18 1471 2.82
  Urban teaching 72,878 97.28 2,038 2.72
Length of stay, mean (SD) 7.37 (0.03) 11.93 (0.24) < 0.001
In-hospital mortality, mean (SD) 0.11 (0.00) 0.27 (0.01) < 0.001
Total charges, mean (SD) 45,951.04 (227.42) 82,812.09 (2,226.03) < 0.001
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ease had higher predisposition to develop GIB with an odds 
ratio (OR) of 8.4 (95% CI: 7.4 - 9.4) and 3.7 (95% CI: 1.4 
- 1.7), respectively. Patients with a history of gastric cancer, di-
verticular bleeding and colon cancer were more likely to have 
GIB. However, patients with gastroesophageal reflux disease 
(GERD) had a relatively lower OR (OR: 0.8; 95% CI: 0.7 - 
0.9) of having a GIB. Furthermore, patients with coagulopathy 
(OR: 3.003; P < 0.001), pancytopenia (OR: 2.6; P < 0.001) 
and anemia (OR: 2.5; P < 0.001) had higher likelihood of de-
veloping GIB. Other conditions which raised the risk of GIB 
included AF and CHF.
On the other hand, comorbidities like coronary artery 
disease (CAD), valvular heart disease, hypertension, COPD, 
diabetes, end-stage renal disease (ESRD), rheumatoid arthritis 
and tobacco use had a relatively lower incidence of GIB.
Table 3 shows the most common causes of ARDS and 
their attributed increased risk of GIB. These included aspira-
tion pneumonia, pancreatitis and sepsis in decreasing order. 
ARDS secondary to burns had lower OR to have a GIB.
Discussion
Our study is the largest to date, where a nationwide analysis of 
the incidence of GIB in individuals admitted to intensive care 
units with ARDS, was performed. Data collected over a decade 
Table 2.  Risk Factors Associated With GIB in Patients With ARDS (CCI: Charlson Comorbidity Index)
Comorbidity Odds ratio 95% confidence interval P value
Gastroesophageal reflux disease 0.754 0.669 0.85 < 0.001
Atrial fibrillation 1.549 1.431 1.676 < 0.001
Cirrhosis 8.356 7.414 9.418 < 0.001
Peptic ulcer disease 3.705 3.079 4.458 < 0.001
Rheumatoid arthritis 0.789 0.571 1.09 0.1354
Valvular heart disease 1.08 0.967 1.205 0.1749
Coronary artery disease 1.063 0.982 1.151 0.1325
Hypertension 1.048 0.983 1.118 0.1547
Chronic obstructive pulmonary disorder 1.041 0.96 1.128 0.3415
Diabetes 0.982 0.909 1.06 0.6351
Tobacco use disorder 0.673 0.583 0.777 < 0.001
Pancytopenia 2.624 1.942 3.544 < 0.001
End-stage renal disease 0.876 0.695 1.104 0.2521
Congestive heart failure 1.388 1.298 1.484 < 0.001
Anemia 2.472 2.312 2.644 < 0.001
Peripheral vascular disease 1.304 1.114 1.525 0.0009
TIA/stroke 1.166 1.033 1.316 0.0126
Weekend admission 1.035 0.962 1.114 0.3617
Coagulopathy 3.003 2.738 3.294 < 0.001
Diverticular bleeding 2.742 1.441 5.218 < 0.001
Esophageal cancer 1.23 0.707 2.14 0.4628
Stomach cancer 3.09 2.035 4.692 < 0.001
Colon cancer 1.813 1.431 2.299 < 0.001
CCI index ≥ 2 2.478 2.294 2.677 < 0.001
Table 3.  Common Etiologies of ARDS and Their Risk for GIB
Cause Odds ratio 95% confidence interval P value
Aspiration pneumonia 2.098 1.916 2.296 < 0.001
Pancreatitis 2.016 1.633 2.49 < 0.001
Sepsis 1.622 1.439 1.828 < 0.001
Pneumonia 0.833 0.776 0.894 < 0.001
Burns 0.385 0.096 1.552 0.1797
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using the NIS database were evaluated. Our findings could be 
summarized by the following: 1) there is an increased inci-
dence of GIB among critically ill patients suffering ARDS par-
ticularly in elderly individuals; 2) the hospital mortality rate 
among ARDS patients with GIB was significantly increased 
compared to the control group who did not develop GIB; 3) 
predictors of GIB included advanced age, cirrhosis and peptic 
ulcer disease; 4) potential causes of ARDS that were statisti-
cally linked to an increased risk of GIB were aspiration pneu-
monia, pancreatitis and sepsis or septic shock; 5) in addition, 
there was a significant increase in overall length of hospital 
stay and attributed health care cost among patients whose 
course of stay was complicated by GIB.
The incidence of GIB among ARDS patients in our study 
reached around 2.67%. This is comparable to a multicenter 
prospective trial by Krag et al, where the authors reported a 
GIB rate of 2.6% (95% CI: 1.6-3.6%) among mechanical-
ly ventilated critically ill patients [3]. Similar results with a 
prevalence ranging from 0.6% to 4% have been reported in 
the literature as well [5, 20]. This is in contrast to the earlier 
reports in 1978 where overt GIB rates were thought to be as 
high as 25% in critically ill patients [21]. This difference could 
be explained in part by an overall improvement in the manage-
ment of critically ill patients, ranging from early aggressive 
resuscitation, institution of early enteral nutrition, as well as 
increasing use of prophylactic acid suppression measures to 
prevent stress ulcer formation [22-24].
An acute or chronic underlying liver disease has been de-
scribed in the literature by Barletta to be an independent risk 
factor for GIB among patients with severe sepsis and septic 
shock [25]. Our data comparably showed a significant in-
creased risk of GIB among ARDS patients with liver cirrhosis 
(OR: 8.36 (95% CI: 0.66 - 0.85); P < 0.0001) and a history of 
peptic ulcer disease (OR: 3.705; P < 0.0001). Other potential 
risk factors that we were able to identify in our ARDS study 
group included coagulopathy, pancytopenia and anemia. Vari-
ous studies in the past have demonstrated an independent cor-
relation between GIB and coagulopathy or thrombocytopenia 
in critically ill patients [3, 5, 26]. Approximately 95% of all 
patients admitted to the intensive care unit are reported to ex-
hibit a drop in their hemoglobin by their third day of stay [27].
Our study elucidated other comorbidities that were inde-
pendently linked to a higher incidence of GIB like AF, CHF 
and history of diverticular bleeding or gastrointestinal malig-
nancies. An earlier retrospective study reported in 2003 by 
Faisy et al analyzed the incidence of GIB in critically ill pa-
tients who received stress ulcer prophylaxis in comparison to 
patients who did not. The patients who developed clinically 
significant GIB were found to have a higher Simplified Acute 
Physiology Score (SAPS II) [22]. Similarly, another study by 
Krag et al demonstrated a higher Sequential Organ Failure As-
sessment (SOFA) score to be an independent risk factor for 
GIB in sick patients admitted to the critical care unit [3]. These 
studies further illustrate the attributed increased risk of GIB in 
critically ill patients with ARDS and multiple other associated 
comorbidities.
On another note, ARDS patients who receive positive 
pressure ventilation (PPV) for >3 days are in particular sus-
ceptible to mucosal damage due to splanchnic hypo-perfusion 
that furthermore worsens when the PEEP levels up to 15 – 20 
cm of H2O [28]. The surviving sepsis guidelines currently rec-
ommend stress ulcer prophylaxis with proton pump inhibitor 
(PPI), especially in mechanically ventilated patients for > 48 
h. This was endorsed despite the lack of high-level evidence 
showing any mortality benefit [29]. The lack of clear ben-
efit with the use of acid suppressants could be hypothesized 
largely due to failure in distinguishing between SRMD- and 
non-SRMD-related bleeding, such as variceal bleeding, vascu-
lar anomalies or diverticular bleeding. Stress ulcer prophylaxis 
does not play a preventative role in the non-SMRD-related 
bleeding.
GERD, nasogastric tubes (NGTs) and duodenogastroe-
sophageal bile reflux are potential proposed mechanisms of 
esophageal injury in critically ill patients [30]. Interestingly, 
our study did not show GERD to be a significant predictor of 
GIB among ARDS patients (OR: 0.754; P < 0.0001). Wilmer et 
al who looked at ventilated patients also noted this interesting 
finding, and recognized that majority of esophageal mucosal 
injury (75%) were secondary to bile reflux and direct NGT 
trauma [31].
Our study showed a substantially increased length of hos-
pital stay and cost of care among patients with ARDS compli-
cated by a GIB.
One of our major findings included a significant increase 
in hospital mortality from 11% to 27% among ARDS patients 
with GIB as compared to the ARDS group without GIB. The 
cause for this is likely to be multifactorial, including severity 
of comorbidities, organ failure and age. However, we cannot 
comment on the long-term outcomes among this population of 
patients after discharge.
The limitation of our study is that data were derived from 
an administrative database, which poses the possibility of in-
correct classification due to coding errors. However, it is im-
portant to note that annual quality assessment of the NIS da-
tabase is employed by the database administrators to maintain 
internal validity. Another limitation of our study is the lack of 
long-term data; as such, we can only assess the short-term in-
patient outcomes and mortality. Moreover, as a retrospective 
observational study, no inferences can be made regarding cau-
sality between risk factors and outcomes. The observed risk 
factors are reported rather as associations.
Conclusions
In summary, our study is the first large-scale population-based 
study in the USA to examine the relationship between GIB 
and ARDS in critically ill patients. We concluded that the in-
cidence of GIB among patients with ARDS is relatively high, 
reaching up to 2.67%. Furthermore, the occurrence of GIB in 
patients with ARDS is associated with an increased mortal-
ity rate, longer hospitalizations and a considerable increase in 
health care cost. Heightened awareness is needed to consider 
early prophylaxis and prevention of this dreaded complication 
in susceptible patients with ARDS, specifically those who pri-
marily had pancreatitis, pneumonia or septic shock. The main 
limitation of our study is related to our reliance on administra-
tive data prepared for the purpose of billing rather than clinical 
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care or research. Further studies, namely, prospective trials, are 
needed to shed more light on this subject.
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